Clinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.

Similar documents
Headache evaluation and management after concussion. Assistant Professor

How do we treat migraine? New SIGN Guidelines

An Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

ADVANCES IN MIGRAINE MANAGEMENT

Headache Pain Generators

Headache. Section 1. Migraine headache. Clinical presentation

1. On how many days in the last 3 months did you miss work or school because of your headaches?

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches

Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:

ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา

Management of headache

Subject: CGRP Inhibitors

ACUTE TREATMENT FOR MIGRAINE. Cristina Tassorelli

Headache A Practical Approach

Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification

Clinical Learning Days November 10, 2017

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.

FINANCIAL DISCLOSURE. No relevant financial relationships

Long-Term Care Updates

Strategies in Migraine Care

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD

Headache Mary D. Hughes, MD Neuroscience Associates

Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

Chronic Daily Headaches

This policy addresses only the type B formulation rimabotulinumtoxinb marketed as Myobloc.

Headache and Facial Pain. Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology

HEADACHE PATHOPHYSIOLOGY

Migraine - whats on the horizon

Headache Assessment In Primary Eye Care

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary

A New Era of Migraine Management: The Challenging Landscape in Prevention

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES

Controlling Migraine Pain

10/19/2018. Disclosures MIGRAINE PROPHYLAXIS. Objectives. Definitions Slide. What do you think the aooe stands for at the end of erenumab-aooe?

Controversy One: Headache and Disability. Robert Shapiro, MD, PhD University of Vermont

Subject: Aimovig (erenumab) Original Effective Date: 7/10/2018. Policy Number: MCP-320. Revision Date(s):

Migraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology

General Patient Information Dr. David A. Branch, M.D.

Headache Questionnaire

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Migraine Treatment What you need to know

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN

Headaches in Pregnancy Before, During, and After

Specific Objectives A. Topics to be lectured and discussed at the plenary sessions

Treatments for migraine

ARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract

A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN

Proposed Project Scope. OPTIMAL USE OnabotulinumtoxinA for the Prevention of Chronic Migraine Clinical Evidence, Policies and Practice

Supraorbital nerve stimulation Cefaly Device - FDA Approved for migraine prevention (also being investigated as acute therapy)

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital

MIGRAINE A MYSTERY HEADACHE

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches

10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67%

Migraine Management. Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital

Mark W. Green, MD, FAAN

Overuse of barbiturate and opioid containing medications for primary headache disorders Description

Overview INTRODUCTION 3/15/2018. Headache Emergencies. Other way to differentiate between them? Is there an easy way to differentiate between them?

Faculty Disclosures. Learning Objectives

What is the Effectiveness of OnabotulinumtoxinA (Botox ) in Reducing the Number of Chronic Migraines (CM) in Patients Years Old?

Outpatient Headache Care Guideline

Medication overuse headache is a severe chronic pain condition that is preventable and treatable. An International Experience

Advances in the Treatment of Migraine

HEADACHE: Benign or Severe Dr Gobinda Chandra Roy

Migraine, Tension, and Cluster Headache: Primary Care for Primary Headaches. Jonathon M. Firnhaber, MD, FAAFP

MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache

HEADACHE. Primary vs Secondary Headaches SNOOP4. Classification of Primary Headaches. Novel Approaches to Diagnosis and Treatment.

By Nathan Hall Associate Editor

Updates in Headache: Assessment and Treatment

Faculty Disclosures. Learning Objectives. Acute Treatment Strategies

The Role of Allergies and Sinus Disorders in Headache & Facial Pain

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders

4/12/2018. ECHO Ontario Chronic Pain Migraine. Migraine Definition and Epidemiology. Migraine - Undertreatment. Migraine - Diagnostic Classification

Treatment Of Medication. Overuse Headache

Emerging Challenges in Primary Care: Brainstorm: A Symposium on Migraine Treatment and Management

Migraine Pathophysiology. Robert E. Shapiro, MD, PhD

Headache Master School Japan-Osaka 2016 II. Management of refractory headaches Case Presentation 2. SUNCT/SUNA: concept, management and prognosis

My patient s pain in the head, is a pain in Greg Jicha, M.D., Ph.D.

Migraine Management. Roger Cady, MD Headache Care Center Springfield, MO

23, 2005 RESIDENT PHYSICIAN:

Understanding Migraines

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

Daniel Kassicieh, DO, FAAN

July 2012 Target Population. Adult patients 18 years or older in primary care settings.

Stuart Weatherby Consultant Neurologist Derriford Hospital. Plymouth

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine

Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital

HEADACHE. Dr Nick Pendleton. September Headache

Adult with headache. Problem-specific video guides to diagnosing patients and helping them with management and prevention

UPDATE IN MIGRAINE MANAGEMENT

Dubai Standards of Care (Migraine)

MIGRAINE A CAUSE OF INTENSE THROBBING; A MINI REVIEW

10/19/12. Headache: Tips and Tools for Management. Michael A. Rogawski, MD, PhD Disclosures

Transcription:

OVERVIEW Refractory headaches and update on novel treatment Definition of refractory headache Treatment approach Medications Neuromodulation In the pipeline Juliette Preston, MD OHSU Headache Center Refractory headache What does it mean? Unresponsiveness to treatment High frequency of headache Severe disability is present All of the above This is a 5- yo woman with migraine without aura since age 1, asthma, hypothyroidism who presented to the Headache Clinic with chronic daily headache. She recalls about - headaches per week until about years when her headaches became daily. There was no trauma or illness preceding the onset of daily headache Her headaches are located behind the eyes, in the forehead, and top of the head. The quality of the pain is throbbing. The intensity of the pain is moderate. Her headaches are associated with sensitivity to light, sound and fatigue. Her headaches are aggravated by movement (routine physical activity). She denies any unilateral conjunctival injection, lacrimation, rhinorrhea, ptosis, aural pressure or agitation/restlessness associated with her headaches. She also denies any visual aura, dysarthria, numbness, tingling or weakness in face, arm or leg associated with her headaches. 5 6 1

She used Imitrex only for her most severe headache, one or twice per week. She tried Amitriptyline, Topamax, and Botox. Exam was normal. MRI brain done the previous year was normal. Does she have refractory migraine? 7 8 Toolbox to define refractory headache 1 st rule: make sure headaches meet criteria for primary headache disorder ( migraine in this case) nd rule: make sure to rule out medication overuse headache. rd rule: Adequate dose of prophylactic agents are used. th rule: Medication trial was done over an appropriate length of time. Medication overuse headache Headache present on >15 days/month. Regular overuse for > months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache. Headaches have worsened 9 10 Medication overuse headache Using triptan, ergots, analgesics > 10 days per month. Using opioid > 8 days per month. Using Butalbital containing products > 5 days per month. For her neck pain, patient has been taking daily Excedrin. Not a refractory headache patient Bigal et al. Headache. 008 11 1

Refractory headache toolbox Clinical Case Primary headache Rule out MOH Adequate dose of prophylactic agents are used Medication trial was done over an appropriate length of time. Tried Amitriptyline at 10 mg for months. Effective dose: 5-100 mg daily (Couch et al. Headache. 010). Tried Topamax at 5 mg for weeks. Effective dose: 50-00 mg ( target 100 mg) for months (Diener et al. Cephalgia. 007) 1 1 Atenolol: 50-00 mg Nadolol :0-160 mg (fewer side effects than Propanolol) Propranolol: 0-0 mg ( short acting - times per day) Amitriptyline : 5-100 mg ( start at 10 mg) Nortriptyline: 5-150 mg ( start at 10 mg) Venlafaxine: 75-5 mg ( start at 7.5 mg) 15 16 Valproate/divalproex: 500-000 mg Topiramate: 50-00 mg ( start at 5 mg) Clinical Case 5 yo woman- did not have refractory headache Medication overuse- treated with bridging therapy: Stop daily Excedrin 6-8 week of daily Meloxicam ( can use Aleve/Celebrex) Limit Sumatriptan to 10 days per month 17 18

Clinical Case After months, she returned to clinic, still with - headaches per week. Resume a preventative- Lisinopril 10 mg daily Lisinopril 5-0 mg daily Candesartan - mg daily (goal 16 mg ) ( Shrader et al. BMJ. 001) At months follow-up, only 1 mild headache per week. 19 0 Refractory headache toolbox Primary headache Rule out MOH Adequate dose of prophylactic agents are used Medication trial was done over an appropriate length of time. Neuromodulation For patients who do no want/tolerate medications ( and/or injections). Trigeminal nerve stimulation Vagal nerve stimulation 1

5 6 Trigeminal nerve stimulator Preventative: 0 min at night Abortive: 60 min Vagal nerve stimulator In 008, University of Oklahoma did a retrospective review of all of the patients in their VNS registry (N= ) and questionnaire about headache was sent. 10 patients met criteria for migraine headache 8/10 (80%) reported a 50% decrease in headache frequency in the first months after stimulator placement, sustained for the following months. ( Lenaerts et al. Cephalalgia 008) 7 8 www.mypurplefriends.com Pathophysiology of Migraine 1 Migraine pathophysiology: lessons from mouse models and human genetics Michel D Ferrari, Lancet Neurology, Volume 1, Issue 1, 015, 65 80 Phase 1: Central Generator Deep nuclei in the brainstem-hyperexcitable Phase : Peripheral mechanism-trigeminal nerve fiber are activated. Neuropeptide are released into vessel wall (meningeal blood vessel) Causing sterile inflammation reaction (vasodilation, plasma extravasation, mast cell degranulation) Phase : Central again Trigeminal nucleus caudalis in lower brainstem Phase : Central Sensitization Ascending signal recruit more neurons ( causing allodynia, photophobia, and phonophobia) 9 x minutes stimulation 5-10 minutes apart ( times per day) 0 5

VNS and Migraine Migraine pathophysiology: lessons from mouse models and human genetics 1 VNS acts on the TNC via the Nucleus tractus solitarius Michel D Ferrari, Lancet Neurology, Volume 1, Issue 1, 015, 65 80 1 OVERVIEW Conclusion: it is safe and may work when given time. May be considered for patients who can not tolerate drugs or drugs are contraindicated ( elderly, pregnant women and children) Definition of refractory headache Treatment approach Medications Neuromodulation In the pipeline 5 6 6

CGRP CGRP level are higher in migraineurs. During migraine attack, level of CGRP increase. Injecting CGRP triggers a migraine. Injecting antibody to CGRP or its receptor decrease migraine frequency Shuster, Nature Reviews, 016 7 8 Summary Not every chronic/daily headache patient is a refractory headache patient. Consider all options including medication ( revisit if dose/length was not appropriate) Consider neuromodulation. By summer, we may be able to add monoclonal antibodies to our toolbox. Thank You 9 7